IMO a lot of investors are trying to put POLY into the traditional Biotech box. The process to FDA approval is similar but beyond that we are embarking on a new frontier. Computational drug design...the results today are groundbreaking. Poly is as much a high-tech firm as a biotech. Really cool stuff imo.